Neuropsychopharmacology, Published online: 05 September 2026; doi:10.1038/s41386-026-02538-4 NMDA subunit 2B-selective negative allosteric modulator satoprodil (BI 1569912) as mono- and adjunctive therapy in patients with major depressive disorder: results from two phase 2 randomized, controlled trials